Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adapalene + clindamycin + nicotinamide is a topical combination formulation used primarily for acne vulgaris treatment. Adapalene, a synthetic retinoid, normalizes follicular keratinization, reduces comedone formation, and promotes skin cell turnover; clindamycin, a lincosamide antibiotic, inhibits bacterial protein synthesis to kill Propionibacterium acnes and reduce inflammation; nicotinamide (vitamin B3) provides anti-inflammatory effects, improves skin barrier function, and reduces sebum production. This triple combination addresses multiple acne pathogenesis factors—comedogenesis, bacterial proliferation, and inflammation—for enhanced efficacy over dual adapalene-clindamycin therapies, applied as a gel once daily.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene + clindamycin + nicotinamide.